Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2943006

CC(C)(C)c1cc(N)no1.N

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
EGFR P00533 2/20 0.40
NPC1 O15118 5/20 0.38
RAB9A P51151 4/20 0.38
RET P07949 2/20 0.36
KDR P35968 3/20 0.36
MAPK14 Q16539 2/20 0.36
HPGD P15428 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3712259 0.95 MEN1 (0.46) MEN1KMT2AEGFRNPC1RAB9A
SCHEMBL1012600 0.80 MEN1 (0.32) MEN1KMT2A
SCHEMBL31319696 0.80 MEN1 (0.32) MEN1KMT2A
SCHEMBL1256324 0.80 MEN1 (0.32) MEN1KMT2A
SCHEMBL23982534 0.77 MEN1 (0.31) MEN1KMT2AEGFR
SCHEMBL11291871 0.77 MEN1 (0.31) MEN1KMT2AEGFR
SCHEMBL769538 0.77 EGFR (0.33) MEN1KMT2AEGFRKDR
SCHEMBL17732311 0.77 HSD17B10 (0.39) MEN1KMT2A
SCHEMBL2677760 0.77 MEN1 (0.31) MEN1KMT2AEGFRNPC1RAB9A
SCHEMBL1013121 0.77 MEN1 (0.31) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
EP-1684762-A4 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORP (US) 2009-06-17 EP disclosed
EP-1684762-A2 UREA DERIVATIVES AS KINASE MODULATORS Ambit Biosciences Corporation (US) 2006-08-02 EP disclosed
US-20050267182-A1 Urea derivatives as FLT-3 modulators AMBIT BIOSCIENCES CORPORATION 2005-12-01 US disclosed
US-20050197371-A1 Urea derivatives as PDGFR modulators AMBIT BIOSCIENCES CORPORATION 2005-09-08 US disclosed
US-20050192314-A1 Urea derivatives as C-kit modulators AMBIT BIOSCIENCES CORPORATION 2005-09-01 US disclosed
US-20050165031-A1 Urea derivatives as ABL modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
US-20050165024-A1 Urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
WO-2005048948-A2 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165024-A1 Urea derivatives as kinase modulators ULK2, ULK1, ULK3 MEN1 4259/4885KMT2A 1390/4885EGFR 971/4885
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS ABL1, ABL2, BCR MEN1 4362/4885KMT2A 285/4885EGFR 196/4885
US-20050192314-A1 Urea derivatives as C-kit modulators KIT, PRKCH, PRKCE MEN1 2079/4885KMT2A 639/4885EGFR 942/4885
US-20050267182-A1 Urea derivatives as FLT-3 modulators FLT4, FLT1, FLT3 MEN1 3423/4885KMT2A 1637/4885EGFR 215/4885
US-20050197371-A1 Urea derivatives as PDGFR modulators PDGFRA, PDGFRB, PDGFA MEN1 4597/4885KMT2A 2832/4885EGFR 17/4885
US-20050165031-A1 Urea derivatives as ABL modulators ABL1, ABL2, BCR MEN1 4362/4885KMT2A 285/4885EGFR 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.